VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS
佛蒙特州 COBRE:项目 3:溶组织内阿米巴吞噬机制
基本信息
- 批准号:7959818
- 负责人:
- 金额:$ 16.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2010-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddendumAffinityAmebiasisAmino Acid SequenceAmoeba genusAntibodiesApoptoticApplications GrantsAreaAsparagineBacteriaBacterial AdhesinsBindingBiologicalBiological AssayBiologyBiotinBiotinylationBovine Serum AlbuminC3biCell LineCell divisionCell surfaceCellsCenters of Research ExcellenceChinese Hamster Ovary CellClinicalCollagenCollectinsCommunicable DiseasesComplementComplement 1qComplement 3bComputer Retrieval of Information on Scientific Projects DatabaseDataDrosophila genusEndoplasmic ReticulumEntamoeba disparEntamoeba histolyticaEnvironmentEscherichia coliFab ImmunoglobulinsFacultyFamily memberFeedbackFlow CytometryFundingGelGenesGenomeGlycocalyxGrantGroup MeetingsHomologous GeneHumanImmunobiologyImmunoglobulin GImmunoglobulinsImmunologyInfectionInstitutionIntestinesJointsJournalsLabelLatex BeadLectinLeishmaniaLeishmania glycoprotein gp63LigandsMalignant Epithelial CellMannose Binding LectinMannose-Binding LectinsManuscriptsMass Spectrum AnalysisMembraneMembrane ProteinsMentorsMetalloproteasesMethodsMicrobiologyMolecularMolecular BiologyMonoclonal AntibodiesNamesNational Institute of Allergy and Infectious DiseaseOpen Reading FramesPaperParasitesPathogenesisPathway interactionsPeptide Sequence DeterminationPeptide Signal SequencesPersonnel ManagementPhagocytosisPlasmidsPlayProcessProductivityProgress ReportsProteinsProtocols documentationPublicationsPublishingPulmonary Surfactant-Associated Protein AReadingRecombinantsResearchResearch PersonnelResourcesRoleRunningScientistSerineSilver StainingSorting - Cell MovementSourceStreptavidinStudentsSurfaceSystemTailTestingTimeUnited States National Institutes of HealthVaccinesVermontVirulenceVisitWorkbasecell killingcell motilitycollegecrosslinkfallsfollow-upgraduate studentimmune resistanceinsightinterestlung Carcinomamacrophagemedical schoolsmeetingsmembermigrationnovelparticlephagocytosis receptorpreventprogramsprotein functionprotein profilingreceptorreceptor bindingresearch studysmall hairpin RNAvaccine candidatevectorvector controlward
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
A.Specific Aims
The ability of the intestinal ameba Entamoeba histolytica to phagocytose host cells correlates with parasite virulence, but the mechanisms underlying this process and its specific contribution to pathogenesis remain unknown. The specific aims were not changed during the last year.
Aim 1: Test the hypothesis that E. histolytica has a phagocytosis receptor specific for the collagenous tail of C1q and the collectins.
Aim 2: Test the hypothesis that the serine-rich E. histolytica protein (SREHP) and/or the related asparagine-rich Ariel proteins function as receptors for phagocytosis of killed cells.
B.Studies and Results
Aim 1: As noted last year, we discovered that E. histolytica phagocytoses apoptotic cells coated with C1q more efficiently than apoptotic cells coated with control proteins. To follow up on this, we developed a method to construct "single-ligand" fluorescent particles by biotinylating protein ligands of interest and using them to coat streptavidin-latex beads. With this system, we demonstrated that C1q alone is a potent stimulant of E. histolytica phagocytosis. Mannose binding lectin (MBL), a collectin family member that is structurally related to C1q by virtue of a common collagen-like tail domain, also stimulated E. histolytica phagocytosis, as did purified collagenous tails from C1q and surfactant protein A (SP-A). Entamoeba histolytica also migrated towards these proteins in transwell assays. These findings were published last October.
We have now used flow cytometry to assay binding of FITC-labeled collectins to the surface of E. histolytica. The results showed that C1q-FITC binds to the amebic surface in a saturable manner, and that binding of C1q-FITC can be partially competed with free MBL. These data provide additional evidence of an amebic receptor specific for the collagenous collectin tail. We are actively engaged in identifying this receptor. Our first approach was to use purified C1q as the bait in cross-linking experiments using the multifunctional cross-linker Sulfo-SBED, which transfers biotin to proteins in close proximity. Our initial experiments were unsuccessful, because the C1q bait forms multimers resulting in overwhelming biotinylation of other bait molecules. A similar approach using purified collagenous tails might work, as might affinity-based methods. An additional approach we have taken is to use flow cytometry to sort amebic trophozoites that are positive or negative for phagocytosis of C1q-coated beads. We have compared the membrane protein profiles of trophozoites positive for phagocytosis of C1q-coated beads to the membrane protein profiles from non-phagocytic trophozoites and those that phagocytosed BSA-coated control beads. Enrichment of specific membrane proteins is observable on silver-stained SDS-PAGE gels. After optimizing our FACS sorting protocol further, we will identify the reproducible bands using mass spectrometry.
Although we found that collagenous tails from SP-A significantly stimulate E. histolytica phagocytosis, intact SP-A actually inhibited phagocytosis. Phagocytosis of SP-A-coated particles was approximately five times lower than basal phagocytosis of beads coated with bovine serum albumin (BSA, negative control). This raises the possibility that the lectin domain of SP-A binds to an inhibitory receptor on the ameba surface, while the SP-A tail stimulates phagocytosis via a common collectin receptor. Consistent with this possibility, SP-A can inhibit or enhance macrophage phagocytosis based on context. That is, in the absence of bacteria or cellular debris, SP-A binds an inhibitory receptor via its lectin domain, but in the presence of bacteria or cellular debris it preferentially binds the debris, which exposes its collagenous tail and stimulates phagocytosis. Our ability to pursue this possibility further has been limited by inadequate quantities of SP-A. Thus, we have developed a method to isolate SP-A from a human lung carcinoma cell line, which we are in the process of optimizing. Once we have adequate amounts of SP-A, we plan to confirm its biological activity with bacterial binding studies and then to use it to further examine if SP-A may have the ability to either stimulate or inhibit E. histolytica phagocytosis depending on the local environment.
Aim 2: Some of our results from aim 2 were published in 2008 in a paper which describes a monoclonal antibody screen we conducted to identify phagocytosis inhibitory antibodies. In this screen, we identified the SREHP as the target of an inhibitory antibody. In follow-up work, we found that the Fab fragment of the inhibitory antibody had no effect on phagocytosis and that recombinant SREHP produced in Escherichia coli had no specific binding activity. The SREHP is a glycoscylated protein, so we want to express it on the surface of Chinese Hamster Ovary Cells and conduct binding studies. The gene has been cloned into the vector pDisplay (which incorporates a mammalian signal peptide and membrane anchor) for this purpose, but the experiment has not yet been completed. In addition, we want to silence expression of the SREHP in amebic trophozoites. We have constructed four plasmids for expression of small hairpin RNAs based on four different SREHP sequences (and a scrambled control vector), but we have not been able to transfect E. histolytica successfully with these constructs.
C. Significance: Entamoeba histolytica's phagocytic ability correlates with virulence and these studies promise to clarify its underlying mechanisms. Aim 1 is focused on clarifying the ligands on apoptotic cells that trigger E. histolytica phagocytosis and on the amebic receptors that bind them. These receptors may be candidates for inclusion in a vaccine to prevent amebiasis. Furthermore, if we confirm that SP-A inhibits or enhances amebic phagocytosis depending on context, then it may suggest a completely novel mechanism by which E. histolytica senses its environment and this could provide critical insights into why E. histolytica is invasive in only about 10% of infections. Successful silencing of the SREHP in aim 2 would extend results of our antibody study, and demonstration of binding of apoptotic cells and/or bacteria to CHO cells expressing the SREHP would definitively demonstrate that this protein functions as an adhesin. Though the SREHP is a leading vaccine candidate, its function is unknown; therefore, this would be very significant.
D. Plans: An R01 grant on the phagocytosis studies in aim 1 was funded by the NIAID in 9/2008. Accordingly, the specific aims will be changed entirely in the coming year if I am allowed to remain on the COBRE grant. The new aims will focus on an E. histolytica homologue to leishmanolysin. Leishmanolysin is an immunodominant surface protein of leishmania promastigotes, and is an M8-type metalloproteinase that degrades complement and immunoglobulins. Interestingly, the Drosophila orthologue invadolysin plays critical roles in cell division and cell migration. We identified two leishmanolysin homologues in the E. histolytica genome, which we named E. histolytica leishmanolysin-like proteins 1 and 2 (EhLMLP-1 and -2). The EhLMLP-1 gene is not present in Entamoeba dispar, a non-pathogenic ameba that is closely related to E. histolytica. Few differences in the protein coding regions have been identified between E. histolytica and E. dispar. This and the importance of leishmanolysin in leishmania virulence make it important to determine the function of EhLMLP-1 and the specific role(s) it plays in E. histolytica biology. We plan to: 1) determine if EhLMLP-1 is a cell surface metalloproteinase; 2) determine if EhLMLP-1 contributes to immune resistance by degrading IgG and converting complement C3b to iC3b; and 3) determine if EhLMLP-1 and -2 function in cell division and migration.
E. Publications (since the 2008 progress report)
Teixeira JE, Heron B, Huston CD. C1q- and collectin-dependent phagocytosis of apoptotic host cells by the intestinal protozoan Entamoeba histolytica. Journal of Infectious Diseases. 2008. 198:1062-1070.
Vaithilingam A, Teixeira JE, Huston CD. Addenda article: Endoplasmic reticulum continuity in the protozoan parasite Entamoeba histolytica: evolutionary implications and a cautionary note. Communicative and Integrative Biology. 2008. 1(2):172-174.
Mentoring Summaries:
Dr. Markus Thali
Dr. Thali meets with Dr. Huston on a monthly basis to discuss research and personnel management issues. He also served on the thesis committee of one of Dr. Huston's graduate student (Brad Heron) and, as the director of the Cell and Molecular Biology Graduate Program, he is somewhat familiar with the progress of the other graduate student in Dr. Huston's lab (Archana Vaithilingam). In addition, since fall 2007, the Huston and the Thali groups meet once a month for a joint group meeting.
Dr. Cory Teuscher
Chris previously had issues with a graduate student that he successfully resolved. We discussed on several occasions his interests and desire to submit a second R01 application. We talked in depth about the two fundamental approaches to successfully running an academic research enterprise: highly focused with sustained productivity in a single area/molecule/pathway vs. broad based with multiple mutually non-exclusive areas of interests and expertise. The strengths and weaknesses of each approach were discussed, particularly from the perspective of a junior faculty member with clinical responsibilities.
Dr. Gary Ward
Dr. Ward meets biannually one-on-one with Dr. Huston to discuss data and the overall direction of Dr. Huston's work, and more frequently on an informal basis when issues related research or personnel management arise. Dr. Ward critically reads and provides feedback to Dr. Huston on his manuscripts and grant applications, and serves on the dissertation committee of one of Dr. Huston's Master's students, Brad Heron. Dr. Ward and Dr. Huston participate in a joint, biweekly lab meeting, which also includes one of the other junior investigators on the COBRE grant, Dr. Matrajt. This data-centered meeting is highly interactive, and an excellent way for Dr. Huston and his students and postdocs to receive regular feedback on the course of their research.
Dr. Ward has made an effort to introduce Dr. Huston to - and facilitate his interactions with - others on campus or in the immediate area that might be helpful to him in his research. For example, Dr. Ward recently nominated Dr. Huston to speak at the annual Dartmouth College Molecular Pathogenesis retreat; his talk was very well received, and he now has a number of new contacts in the Dept of Microbiology and Immunology at Dartmouth Medical School. Dr. Ward also provides every opportunity to Dr. Huston to meet with visiting scientists and seminar speakers who come to UVM.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHRISTOPHER D HUSTON其他文献
CHRISTOPHER D HUSTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHRISTOPHER D HUSTON', 18)}}的其他基金
Methods to study Cryptosporidium drug resistance
研究隐孢子虫耐药性的方法
- 批准号:
10591168 - 财政年份:2022
- 资助金额:
$ 16.64万 - 项目类别:
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development
重新利用 EMD-Serono“迷你库”进行隐孢子虫药物开发
- 批准号:
10320256 - 财政年份:2019
- 资助金额:
$ 16.64万 - 项目类别:
Preclinical optimization of a parasiticidal drug for cryptosporidiosis
隐孢子虫病杀寄生虫药物的临床前优化
- 批准号:
10356051 - 财政年份:2019
- 资助金额:
$ 16.64万 - 项目类别:
Preclinical optimization of a parasiticidal drug for cryptosporidiosis
隐孢子虫病杀寄生虫药物的临床前优化
- 批准号:
10569660 - 财政年份:2019
- 资助金额:
$ 16.64万 - 项目类别:
Repurposing the EMD-Serono "mini-library" for Cryptosporidium drug development
重新利用 EMD-Serono“迷你库”进行隐孢子虫药物开发
- 批准号:
10548847 - 财政年份:2019
- 资助金额:
$ 16.64万 - 项目类别:
Novel approaches to develop a treatment for cryptosporidiosis
开发隐孢子虫病治疗方法的新方法
- 批准号:
8605836 - 财政年份:2013
- 资助金额:
$ 16.64万 - 项目类别:
Novel approaches to develop a treatment for cryptosporidiosis
开发隐孢子虫病治疗方法的新方法
- 批准号:
8511900 - 财政年份:2013
- 资助金额:
$ 16.64万 - 项目类别:
VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS
佛蒙特州 COBRE:项目 3:溶组织内阿米巴吞噬机制
- 批准号:
8360773 - 财政年份:2011
- 资助金额:
$ 16.64万 - 项目类别:
VERMONT COBRE: PROJECT 3: MECHANISM OF ENTAMOEBA HISTOLYTICA PHAGOCYTOSIS
佛蒙特州 COBRE:项目 3:溶组织内阿米巴吞噬机制
- 批准号:
8167732 - 财政年份:2010
- 资助金额:
$ 16.64万 - 项目类别:
Molecular Mechanism of Entamoeba histolytica phagocytosis
溶组织内阿米巴吞噬作用的分子机制
- 批准号:
7916951 - 财政年份:2009
- 资助金额:
$ 16.64万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 16.64万 - 项目类别:
Continuing Grant